博拓生物 (688767)
Hangzhou Biotest Biotech Co., Ltd.
K-Line Chart
No K-line data available
Company NameHangzhou Biotest Biotech Co., Ltd.
Listing Date2021-09-08
Issue Price34.55RMB
Registered Capital14933.333410k RMB
Legal RepresentativeChen Yinlong
Registered AddressNo. 17 Futai Road, Zhongtai Street, Yuhang District, Hangzhou City, Zhejiang Province
IndustryMedical Devices
Main BusinessR&D, production, and sales of POCT diagnostic reagents
Company ProfileBiotest is a national high-tech enterprise specializing in the R&D, manufacturing, sales, and service of in vitro diagnostic reagents and instruments. Founded in 2008, the company is headquartered in the scenic Zhongtai Ecological Industrial Park in Yuhang District, Hangzhou. The factory covers a construction area of 25,000 square meters with a registered capital of 80 million yuan. Biotest's products cover multiple fields of medical testing. Its leading products are rapid diagnostic reagents, which include five major series: pregnancy testing, infectious disease testing, drug abuse testing, tumor marker testing, and cardiac marker testing. These are widely used in hospitals at all levels, disease control centers, blood stations, drug rehabilitation centers, and third-party testing institutions. The company has passed the German TÜV ISO13485 quality system certification, and many of its products have obtained China CFDA registration and EU CE certification. The products are sold to more than 80 countries and regions worldwide. Biotest places great emphasis on independent R&D and technological accumulation, having established an innovative and pioneering R&D team. The company possesses three major technology R&D platforms: rapid diagnostic reagents, biological raw materials, and POCT, providing the enterprise with multiple patented technologies and innovative product developments annually. It also has a marketing team with rich sales management experience, offering comprehensive professional services to end customers and channel partners.
Stock Details
1. Key Indicators
- Total Shares(W): 14933.33
- Circulating A-Shares(W): 14933.33
- Earnings Per Share(RMB): 0.1400
- Net Assets Per Share(RMB): 15.6599
- Operating Revenue(W RMB): 30807.11
- Total Profit(W RMB): 2273.20
- **Net Profit Attributable to Parent(W RMB) **: 2226.32
- Net Profit Growth Rate(%): -75.04
- Weighted Return on Equity(%): 0.9400
- Operating Cash Flow Per Share(RMB): 0.4960
- Undistributed Profit Per Share(RMB): 9.4104
- Capital Reserve Per Share(RMB): 5.0664
2. Main Business
The main business covers:
- Research, development, production, and sales of POCT diagnostic reagents
3. Company Basic Information
- Company Name: Hangzhou Biotest Biotech Co., Ltd.
- Listing Date: 2021-09-08
- Industry: Pharmaceutical Manufacturing
- Address: No. 17 Futai Road, Zhongtai Street, Yuhang District, Hangzhou City, Zhejiang Province
- Website: https://www.biotests.com.cn/
- Company Profile: The company was established through the overall change of the limited company and focuses on the research, development, production, and sales of POCT diagnostic reagents.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hangzhou Tuokang Investment Co., Ltd. | General Legal Person | 3485.44 | 23.34 |
| 2 | Hangzhou Kangyu Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 1680.00 | 11.25 |
| 3 | Hangzhou Biotest Biotech Co., Ltd. - 2024 Employee Stock Ownership Plan | Asset Management Plan | 301.00 | 2.02 |
| 4 | China Europe Enjoy Life Mixed Securities Investment Fund Class A | Fund | 217.87 | 1.46 |
| 5 | Fuguo Positive Growth One-Year Regular Open Mixed Securities Investment Fund | Fund | 61.38 | 0.41 |
| 6 | China Europe Industry Prosperity One-Year Holding Period Mixed Securities Investment Fund Class A | Fund | 28.78 | 0.19 |
| 7 | China Europe Industry Xuanxuan Mixed Securities Investment Fund Class A | Fund | 4.24 | 0.03 |
5. Concept Sectors
- Brain-Computer Interface
- Helicobacter Pylori
- Hepatitis Concept
- Margin Trading & Securities Lending
- Overseas Business
Remarks
- Data update date: 2025-11-05
- Data source: Public Market Information